Drug Monograph
Imbruvica (Ibrutinib)
ibrutinib
Pharmacokinetic Profile
Half-Life
4–6 hours
Metabolism
CYP3A4 (major), CYP2D6 (minor)
Protein Binding
97.3%
Bioavailability
Low (~3.9% fasting); ~2-fold increase with food
Volume of Distribution
~10,000 L (apparent)
Clinical Information
Drug Class
Bruton Tyrosine Kinase (BTK) Inhibitor
Available Doses
Caps: 70 mg, 140 mg; Tabs: 140 mg, 280 mg, 420 mg; Susp: 70 mg/mL
Route
Oral
Renal Adjustment
Not required (not renally eliminated)
Hepatic Adjustment
Yes — reduce dose; avoid in severe (Child-Pugh C)
Pregnancy
Contraindicated — fetal harm in animal studies
Lactation
Not recommended — advise not to breastfeed
Schedule / Legal Status
Prescription only (not a controlled substance)
Generic Available
Tentative FDA approval (2025); exclusivity limitations apply
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Chronic lymphocytic leukemia / Small lymphocytic lymphoma (CLL/SLL) | Adults | Monotherapy, or combination with rituximab, obinutuzumab, or BR | FDA Approved |
| CLL/SLL with 17p deletion | Adults | Monotherapy or combination | FDA Approved |
| Waldenström macroglobulinemia (WM) | Adults | Monotherapy or combination with rituximab | FDA Approved |
| Chronic graft-versus-host disease (cGVHD) | Adults and pediatric patients ≥1 year | After failure of ≥1 line of systemic therapy | FDA Approved |
Ibrutinib transformed the management of CLL/SLL and WM by offering a continuous oral therapy that avoids conventional cytotoxic chemotherapy. In CLL, it is used across treatment lines—as frontline monotherapy, in combination with anti-CD20 antibodies, or for relapsed/refractory disease, including high-risk populations with del(17p) or TP53 mutation. In WM, ibrutinib is the first approved targeted therapy for this rare lymphoplasmacytic lymphoma. The cGVHD indication covers both adult and pediatric patients who have progressed on at least one prior systemic regimen.
Off-Label Uses
Mantle cell lymphoma (MCL): Previously held accelerated FDA approval, voluntarily withdrawn in May 2023 after confirmatory trials did not demonstrate sufficient clinical benefit for full approval. Still used in practice for relapsed/refractory MCL at 560 mg daily at some centres based on single-arm response data. Evidence quality: Moderate.
Marginal zone lymphoma (MZL): Accelerated approval was also withdrawn in May 2023 alongside MCL. Evidence quality: Low.
Primary CNS lymphoma: Phase Ib data showed high response rates when combined with chemotherapy in patients harbouring CD79B and/or MYD88 mutations. Evidence quality: Low (early-phase).
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| CLL/SLL — treatment-naïve, monotherapy | 420 mg once daily | 420 mg once daily | 420 mg/day | Continue until progression or intolerance No titration required |
| CLL/SLL — in combination with obinutuzumab | 420 mg once daily | 420 mg once daily | 420 mg/day | Start ibrutinib on Day 1 of Cycle 1; give ibrutinib before obinutuzumab on same day Ibrutinib continues as monotherapy after completion of obinutuzumab |
| CLL/SLL — in combination with BR (relapsed) | 420 mg once daily | 420 mg once daily | 420 mg/day | Ibrutinib continues as single agent after BR completion Administer ibrutinib before rituximab on same day |
| CLL/SLL with del(17p) — any line | 420 mg once daily | 420 mg once daily | 420 mg/day | Standard dose regardless of risk profile Indefinite treatment; monitor closely for progression |
| Waldenström macroglobulinemia — monotherapy | 420 mg once daily | 420 mg once daily | 420 mg/day | Continue until progression or intolerance IgM flare may occur in early weeks — not an indicator of failure |
| Waldenström macroglobulinemia — with rituximab | 420 mg once daily | 420 mg once daily | 420 mg/day | Ibrutinib continues beyond rituximab course Give ibrutinib prior to rituximab on same day |
| Chronic GVHD — adults (≥12 years) | 420 mg once daily | 420 mg once daily | 420 mg/day | After failure of ≥1 systemic therapy Discontinue when cGVHD no longer requires therapy |
| Chronic GVHD — pediatric (1 to <12 years) | 240 mg/m² once daily | 240 mg/m² once daily | 420 mg/day | BSA-based dosing; use capsules, tablets, or oral suspension See PI Table 1 for BSA-specific dosing |
Hepatic Impairment Adjustments
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| B-cell malignancy — mild hepatic impairment (Child-Pugh A) | 140 mg once daily | 140 mg once daily | 140 mg/day | 67% dose reduction from standard Monitor more frequently for adverse reactions |
| B-cell malignancy — moderate hepatic impairment (Child-Pugh B) | 70 mg once daily | 70 mg once daily | 70 mg/day | 83% dose reduction from standard Use 70 mg capsule |
| B-cell malignancy — severe hepatic impairment (Child-Pugh C) | AVOID — Do not use | Insufficient data; significant exposure increase expected | ||
Clinical Pearl: Dose Modifications for Adverse Reactions
For Grade 3 or 4 non-hematologic toxicities, interrupt ibrutinib until resolution to Grade 1 or baseline. For the first occurrence, resume at 280 mg daily; for the second, reduce to 140 mg daily; discontinue after a third occurrence. Cardiac toxicity requires more aggressive management—Grade 3 or 4 cardiac failure at first occurrence requires permanent discontinuation.
Pharmacology
Mechanism of Action
Ibrutinib is a first-in-class, small-molecule covalent inhibitor of Bruton tyrosine kinase (BTK). It binds irreversibly to cysteine-481 in the BTK active site via its acrylamide warhead, producing sustained inhibition of BTK enzymatic activity that outlasts its plasma half-life. Because BTK recovery requires de novo protein synthesis, once-daily dosing achieves near-complete receptor occupancy throughout the dosing interval. BTK occupies a critical node in B-cell receptor (BCR) signalling, and its inhibition disrupts downstream NF-kB, ERK1/2, and PI3K/Akt activation, leading to reduced malignant B-cell proliferation, survival, adhesion, and tissue homing. Clinically, this translates into rapid lymph node regression accompanied by a transient redistribution lymphocytosis in the first weeks of therapy—a pharmacodynamic effect rather than treatment failure. Ibrutinib also targets several other kinases at clinically relevant concentrations, including ITK, TEC, EGFR, and CSK, which account for both therapeutic breadth (T-cell modulation in cGVHD via ITK) and off-target toxicities (cardiac arrhythmias linked to CSK/TEC inhibition).
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapid; median Tmax 1–2 h; absolute bioavailability ~3.9% (fasting); food increases exposure ~2-fold | Administer with or shortly after food for consistent exposure; low bioavailability driven by extensive first-pass metabolism |
| Distribution | Apparent Vd ~10,000 L; protein binding 97.3% (concentration-independent) | Extremely high apparent volume suggests extensive tissue distribution; high protein binding limits displacement interactions |
| Metabolism | Hepatic via CYP3A4 (primary), CYP2D6 (minor); active metabolite PCI-45227 (dihydrodiol, ~15x less potent against BTK) | Strong CYP3A4 dependence creates clinically significant interaction potential; avoid strong CYP3A4 inhibitors/inducers |
| Elimination | t½ 4–6 h; CL/F ~1,000 L/h; 80% faecal (mainly metabolites), 10% renal; ~90% excreted within 168 h | Short plasma half-life but sustained pharmacodynamic effect due to irreversible BTK binding; no dose adjustment for renal impairment |
Side Effects
Adverse reaction data below are derived from the pooled safety population of 1,476 patients with B-cell malignancies who received ibrutinib in six clinical trials (FDA PI, revised October 2025). Patients with CLL/SLL comprised the majority of the safety database.
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhea | 34–59% | Usually low-grade and self-limiting; onset often within first months; loperamide can be used for symptom control |
| Fatigue | 30–80% | Broadly reported across trials (range reflects monotherapy vs combination); usually Grade 1–2 |
| Musculoskeletal pain | 21–61% | Includes arthralgia, myalgia, and bone pain; arthralgia especially common (up to 41% in E1912) |
| Bruising | 12–39% | Reflects platelet dysfunction (not thrombocytopenia); usually cosmetic; increased with antiplatelet agents |
| Rash | 21–49% | Often mild maculopapular; Grade 3+ in 3–4% of patients; discontinuation rarely needed |
| Nausea | 12–40% | Grade 3 rare (≤2%); usually transient and does not require antiemetic prophylaxis |
| Thrombocytopenia (lab) | 34–69% | All grades; Grade 3/4 in 5–16% depending on trial; monitor CBC monthly |
| Neutropenia (lab) | 48–66% | All grades; Grade 3/4 in 23–61% (highest with BR combo); G-CSF may be needed |
| Anemia (lab) | 17–43% | All grades; Grade 3/4 rare with monotherapy (0–4%); more common in combination regimens |
| Hypertension | 11–42% | Cumulative; Grade 3+ in 4–19%; median onset ~5.9 months; requires active BP management |
| Upper respiratory tract infection | 14–29% | Usually mild; Grade 3+ uncommon (≤2%) |
| Hemorrhage (any) | 19–39% | Includes bruising/petechiae; major hemorrhage (≥Grade 3) in 4.2% across 2,838 patients; fatalities in 0.4% |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Atrial fibrillation | 6–12% | Cumulative incidence ~13.8% at 36 months; Grade 3/4 in 3–5%; manageable in most patients without discontinuation |
| Pneumonia | 7–16% | Grade 3+ in 4–12%; includes bacterial and opportunistic (PJP); consider prophylaxis in high-risk patients |
| Peripheral edema | 9–28% | Usually Grade 1–2; diuretic-responsive |
| Stomatitis | 14–22% | Includes oral ulceration; Grade 3 uncommon (~1%) |
| Constipation | 12–17% | Grade 3 rare (≤1%) |
| Skin infection | 6–16% | Includes cellulitis; Grade 3+ in 1–3% |
| Second primary malignancy | 10% | Non-melanoma skin cancer most common (6%); non-skin carcinomas in 3.9% |
| Muscle spasms | 5–19% | Usually Grade 1; no specific intervention required |
| Hyperuricemia | 10–19% | Monitor uric acid; TLS prophylaxis in high tumour-burden patients |
Serious
Serious Adverse Effects (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Major hemorrhage (≥Grade 3) | 4.2% | Any time; risk increases with anticoagulants | Hold ibrutinib; manage bleeding; withhold 3–7 days pre/post-surgery; fatalities in 0.4% |
| Cardiac arrhythmias (Grade 3+ AF/flutter) | 3.7% | Cumulative; median onset variable (months to years) | ECG; cardiology referral; rate/rhythm control; dose modification per PI; consider DOAC for stroke prevention (avoid warfarin if possible) |
| Cardiac failure (Grade 3+) | 1.3% | Months after initiation | Echocardiogram; Grade 3/4 at first occurrence requires permanent discontinuation |
| Cardiac death / sudden death | ~1% | Any time during treatment | Baseline cardiac evaluation; vigilant monitoring in patients with cardiac comorbidities |
| Ventricular tachyarrhythmias (Grade 3+) | 0.2% | Early (median ~65 days in case series) | Urgent cardiology evaluation; permanent discontinuation |
| Grade 3+ infections | 21% | Throughout treatment | Evaluate promptly; treat aggressively; consider PJP and antifungal prophylaxis; cases of PML reported |
| Drug-induced liver injury (DILI) | Rare (case reports) | Variable | Monitor LFTs; withhold if suspected DILI; permanently discontinue if confirmed |
| Tumour lysis syndrome (TLS) | Rare | Early treatment cycles; high tumour burden | Assess baseline risk; hydration and urate-lowering prophylaxis; monitor electrolytes |
Discontinuation
Discontinuation Rates
CLL/SLL Monotherapy Trials
4–10%
Top reasons: Pneumonia, hemorrhage, atrial fibrillation, neutropenia, arthralgia, rash, thrombocytopenia
WM Trials
~5%
Top reason: Atrial fibrillation was the most common reason for treatment cessation
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Atrial fibrillation | Most common single reason | Manageable in ~85% of cases without discontinuation; dose interruption effective in many patients |
| Pneumonia | Grade 3+ in 4–12% | Both conventional and opportunistic; prophylaxis should be considered |
| Hemorrhage | Major in 4.2% | Fatal events reported in 0.4%; withhold peri-operatively |
| Arthralgia | Variable | Usually manageable; rarely requires discontinuation unless severe and persistent |
Managing Atrial Fibrillation on Ibrutinib
Atrial fibrillation is the most clinically challenging adverse effect of ibrutinib. Key management points: (1) most patients (~85%) can continue ibrutinib with appropriate rate or rhythm control; (2) avoid warfarin due to compounded bleeding risk—DOACs are preferred for stroke prevention; (3) dose reduction may decrease recurrence risk; (4) outcomes after ibrutinib discontinuation for CLL/SLL are poor, so continuation with AF management is generally preferred over stopping therapy.
Drug Interactions
Ibrutinib is extensively metabolised by CYP3A4, making it highly susceptible to pharmacokinetic interactions with CYP3A modulators. Co-administration with a strong CYP3A4 inhibitor (ketoconazole) increased ibrutinib AUC by 24-fold and Cmax by 29-fold. This interaction dominates clinical prescribing decisions. Ibrutinib itself does not significantly inhibit major CYP450 enzymes at therapeutic concentrations.
Major
Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin)
MechanismPotent CYP3A4 inhibition reduces first-pass metabolism
EffectUp to 24-fold increase in ibrutinib exposure; dramatically elevated toxicity risk
ManagementAvoid concomitant use. If short-term use required (≤7 days, e.g., anti-infectives), interrupt ibrutinib. Resume ibrutinib after inhibitor is cleared.
FDA PI
Major
Posaconazole (high-dose)
MechanismStrong CYP3A4 inhibition (dose-dependent)
EffectMarked increase in ibrutinib plasma concentrations
ManagementFor B-cell malignancies: reduce ibrutinib to 70 mg daily with high-dose posaconazole (suspension 200 mg TID/400 mg BID, IV 300 mg daily, or DR tablets 300 mg daily). Low-dose posaconazole: reduce ibrutinib to 140 mg daily.
FDA PI
Major
Voriconazole
MechanismStrong CYP3A4 inhibition
EffectSignificantly elevated ibrutinib levels
ManagementReduce ibrutinib to 140 mg daily for B-cell malignancies; 280 mg daily for cGVHD patients ≥12 years
FDA PI
Moderate
Moderate CYP3A4 Inhibitors (fluconazole, erythromycin, diltiazem, verapamil)
MechanismPartial CYP3A4 inhibition
EffectModerate increase in ibrutinib exposure
ManagementReduce ibrutinib to 280 mg daily for B-cell malignancies. No reduction needed for cGVHD (maintain 420 mg).
FDA PI
Major
Strong CYP3A4 Inducers (rifampin, carbamazepine, phenytoin, St. John’s Wort)
MechanismCYP3A4 induction accelerates ibrutinib clearance
EffectMarked reduction in ibrutinib exposure; potential loss of therapeutic efficacy
ManagementAvoid concomitant use. No dose increase recommendation can compensate for this interaction.
FDA PI
Moderate
Warfarin
MechanismAdditive bleeding risk (ibrutinib inhibits platelet function + warfarin anticoagulation)
EffectSignificantly elevated major hemorrhage risk
ManagementAvoid warfarin if possible. If anticoagulation needed, prefer DOACs (note: apixaban and rivaroxaban levels may be affected by CYP3A4 interactions). Close monitoring essential.
FDA PI / Expert consensus
Moderate
Antiplatelet Agents
MechanismAdditive platelet dysfunction
EffectIncreased major hemorrhage: 4.4% with antiplatelets vs 3.1% without
ManagementWeigh risk-benefit carefully; monitor for bleeding signs; fish oil supplements also have antiplatelet effects
FDA PI
Minor
Grapefruit / Seville Oranges
MechanismIntestinal CYP3A4 inhibition
EffectIncreased ibrutinib bioavailability (grapefruit juice increased bioavailability to 15.9% from 3.9%)
ManagementAvoid grapefruit and Seville oranges during treatment
FDA PIMonitoring
-
Complete Blood Count
Monthly
Routine Monitor for neutropenia (Grade 3/4 in 23% as single agent), thrombocytopenia (Grade 3/4 in 8%), and anaemia. More frequent monitoring during initial months and with combination regimens. -
Blood Pressure
Each visit; ongoing
Routine Hypertension occurs in 19% of patients and is cumulative over time. Initiate or adjust antihypertensive therapy as needed. Grade 3+ hypertension requires dose modification. -
Cardiac Function
Baseline + as indicated
Routine Baseline cardiac history and ECG. Evaluate with ECG and echocardiogram for symptoms of arrhythmia (palpitations, syncope, dyspnoea) or new-onset cardiac failure. Higher vigilance in patients with existing cardiac risk factors. -
Hepatic Function
Baseline, then periodically
Routine Bilirubin and transaminases at baseline and throughout treatment. Increase monitoring frequency if abnormal. Cases of severe drug-induced liver injury have been reported with BTK inhibitors. -
Bleeding Signs
Each visit; ongoing
Routine Assess for bruising, petechiae, and signs of major haemorrhage. Particularly important in patients on concomitant anticoagulants or antiplatelets. Plan ibrutinib interruption 3–7 days before and after surgical procedures. -
Infection Surveillance
Each visit; as needed
Routine Evaluate fevers promptly. Grade 3+ infections in 21%. Consider PJP and antifungal prophylaxis (especially aspergillosis risk). Cases of PML reported—evaluate new neurological symptoms urgently. -
Skin Examination
Baseline, then annually
Routine Second primary malignancies reported in 10% of patients; non-melanoma skin cancer is the most frequent (6%). Annual dermatological review recommended. -
Uric Acid
Baseline; high-risk patients
Trigger-based Assess tumour lysis syndrome risk in patients with high tumour burden. Provide hydration and urate-lowering prophylaxis as appropriate. -
Pregnancy Status
Before initiation
Trigger-based Verify pregnancy status in females of reproductive potential before starting. Advise effective contraception during treatment and for 1 month after the last dose.
Contraindications & Cautions
Absolute Contraindications
- Pregnancy: Animal studies demonstrated embryo-fetal toxicity including malformations at exposures 3–20 times the human dose. Ibrutinib must not be used in pregnant women.
- Severe hepatic impairment (Child-Pugh C): Markedly increased drug exposure expected due to CYP3A4-dependent metabolism. Use is not recommended.
Relative Contraindications (Specialist Input Recommended)
- Active severe bleeding or recent CNS haemorrhage: Given the 4.2% rate of major haemorrhage and 0.4% fatality rate, active significant bleeding warrants specialist-guided risk-benefit assessment before initiation or continuation.
- Concomitant strong CYP3A4 inhibitor therapy (chronic): Avoid if possible due to up to 24-fold exposure increase. If unavoidable short-term, specific dose modifications are required.
- Concomitant strong CYP3A4 inducer therapy: Markedly reduces ibrutinib efficacy; avoid combination. Alternative agents or alternative targeted therapy should be considered.
- Pre-existing uncontrolled atrial fibrillation or severe cardiac failure: Ibrutinib compounds these risks. Cardiology co-management is essential before initiating therapy.
- Planned major surgery within 3–7 days: Withhold ibrutinib peri-operatively due to haemorrhagic risk; timing depends on surgery type and bleeding risk.
Use with Caution
- Mild or moderate hepatic impairment: Dose reduction required (140 mg for Child-Pugh A; 70 mg for Child-Pugh B in B-cell malignancy indications); monitor more frequently.
- Patients on anticoagulants or antiplatelet agents: Compounded bleeding risk—3.1% major haemorrhage without, 4.4% with antiplatelets, 6.1% with anticoagulants.
- Elderly patients (≥65 years): Higher rates of cardiac events (AF, hypertension), infections (pneumonia, cellulitis), and gastrointestinal effects reported.
- Patients with hypertension or diabetes mellitus: Greater susceptibility to cardiac arrhythmias and cardiac failure.
- Immunocompromised patients: Higher risk of opportunistic infections including PJP and aspergillosis; consider prophylaxis.
- Patients scheduled for plasmapheresis (WM): Administer ibrutinib after plasmapheresis on the same day.
FDA Class-Wide Safety Advisory
Cardiac Arrhythmias, Cardiac Failure, and Sudden Death — BTK Inhibitors
Fatal and serious cardiac arrhythmias and cardiac failure have been reported with ibrutinib. Deaths attributable to cardiac causes or sudden death occurred in approximately 1% of 4,896 patients across clinical trials. Grade 3 or greater atrial fibrillation/flutter was reported in 3.7%, and Grade 3 or greater cardiac failure in 1.3%. These events occurred in patients with and without pre-existing cardiac disease. Clinicians should evaluate cardiac history and function at baseline, monitor throughout treatment, and manage events according to dose modification guidelines in the prescribing information.
FDA Class-Wide Safety Advisory
Hepatotoxicity, Including Drug-Induced Liver Injury — BTK Inhibitors
Severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI) have been reported with Bruton tyrosine kinase inhibitors, including ibrutinib. Clinicians should evaluate bilirubin and transaminases at baseline and throughout treatment. If DILI is suspected, withhold ibrutinib; upon confirmation, discontinue permanently.
Patient Counselling
Purpose of Therapy
Ibrutinib works by blocking a protein called BTK that cancer cells need to grow and survive. It is not a conventional chemotherapy. Instead, it is a daily oral targeted therapy taken continuously to keep the disease under control. Most patients experience a response that deepens over months to years of treatment. Temporary swelling of lymph nodes or an increase in white blood cell count early in therapy is expected and does not mean the treatment is failing.
How to Take
Take ibrutinib once daily at approximately the same time each day. Swallow tablets or capsules whole with water—do not crush, chew, or open capsules. Taking the medication with food or shortly after a meal improves absorption and provides more consistent drug levels. If a dose is missed, take it as soon as remembered on the same day, then return to the normal schedule the next day. Never double up on doses.
Bleeding & Bruising
Tell patient
Ibrutinib affects platelet function and may increase bleeding or bruising. This is usually minor (easy bruising, petechiae) but serious bleeding can occur. Avoid activities with high injury risk. Inform all healthcare providers including dentists that you are taking ibrutinib. Avoid over-the-counter NSAIDs unless discussed with your oncologist. Stop fish oil supplements unless advised otherwise.
Call prescriber
Blood in urine or stools, black tarry stools, prolonged nosebleeds, vomiting blood, severe headache with vision changes, or any unexpected heavy bleeding.
Heart Rhythm Changes
Tell patient
Ibrutinib can cause irregular heartbeat (atrial fibrillation) in some patients. This is treatable and does not always require stopping the medication. Report any new symptoms promptly so they can be managed early.
Call prescriber
Palpitations, racing or fluttering heartbeat, dizziness or lightheadedness, fainting, unusual shortness of breath, or chest discomfort.
Infection Risk
Tell patient
Your immune system may be less effective while on ibrutinib. Practice good hand hygiene. Stay up to date with vaccinations as advised by your oncology team (avoid live vaccines). Avoid close contact with people who are acutely unwell.
Call prescriber
Fever ≥38°C (100.4°F), chills, persistent cough, painful urination, flu-like symptoms that worsen, or any sign of infection.
Diarrhea
Tell patient
Loose stools are common, especially in the first few months. Stay well hydrated. Loperamide (Imodium) may be used for symptom relief. Diarrhea usually improves over time without needing to change the dose.
Call prescriber
More than 6 episodes of diarrhea per day, blood in stools, signs of dehydration (dizziness, dark urine, dry mouth), or diarrhea lasting more than 48 hours despite loperamide.
Blood Pressure
Tell patient
Ibrutinib can raise blood pressure, sometimes requiring new or additional blood pressure medications. Home BP monitoring is recommended if feasible. The effect can be gradual, so continued monitoring is important even after months on therapy.
Call prescriber
Consistently elevated readings (>140/90 mmHg) on home monitoring, severe headache, visual disturbances, or chest pain.
Drug & Food Interactions
Tell patient
Many medications can interfere with ibrutinib by changing its blood levels. Always inform your oncologist and pharmacist before starting any new prescription, over-the-counter medication, or herbal supplement, especially antifungal drugs and antibiotics. Avoid grapefruit, Seville oranges, and St. John’s Wort.
Call prescriber
Before starting any new medication, including those from other specialists or over-the-counter products.
Surgery & Dental Procedures
Tell patient
Ibrutinib needs to be paused before and after surgical or dental procedures due to bleeding risk. Your oncologist will advise on timing (usually 3–7 days before and after). Always inform surgeons and dentists that you take ibrutinib.
Call prescriber
Whenever any procedure is being planned, including dental extractions, biopsies, or minor surgeries.
Pregnancy & Contraception
Tell patient
Ibrutinib can cause serious harm to an unborn baby. Women of childbearing potential must use effective contraception during treatment and for at least 1 month after the last dose. Do not breastfeed while taking ibrutinib. Men should also discuss family planning with their oncologist.
Call prescriber
If you become pregnant or suspect you may be pregnant while on treatment.
Sources
Regulatory (PI / SmPC)
- Imbruvica (ibrutinib) prescribing information. Pharmacyclics LLC / AbbVie Inc. Revised October 2025. FDA Label Primary source for all dosing, indications, adverse reactions, warnings, and pharmacokinetic data used in this monograph.
- Imbruvica Summary of Product Characteristics (SmPC). European Medicines Agency. EMA European regulatory reference for ibrutinib; provides additional PK data and European-specific prescribing guidance.
Key Clinical Trials
- Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223. doi:10.1056/NEJMoa1400376 RESONATE trial; pivotal Phase 3 study demonstrating superiority of ibrutinib over ofatumumab in relapsed/refractory CLL.
- Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. doi:10.1056/NEJMoa1509388 RESONATE-2 trial; established ibrutinib as frontline therapy for elderly CLL patients vs chlorambucil.
- Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated CLL/SLL (HELIOS). Lancet Oncol. 2016;17(2):200–211. doi:10.1016/S1470-2045(15)00443-4 HELIOS trial; demonstrated PFS benefit of adding ibrutinib to BR in relapsed CLL.
- Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of CLL (iLLUMINATE). Lancet Oncol. 2019;20(1):43–56. doi:10.1016/S1470-2045(18)30788-5 iLLUMINATE trial; ibrutinib-obinutuzumab combination in treatment-naïve CLL.
- Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443. doi:10.1056/NEJMoa1817073 E1912 trial; demonstrated superiority of ibrutinib-rituximab over FCR in younger (≤70) treatment-naïve CLL patients.
- Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378(25):2399–2410. doi:10.1056/NEJMoa1802917 INNOVATE trial; established ibrutinib-rituximab combination in WM with 75% reduction in progression or death.
Guidelines
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 1.2025. NCCN Current treatment algorithm positioning ibrutinib among frontline and relapsed CLL/SLL therapeutic options.
Mechanistic / Basic Science
- Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075–13080. doi:10.1073/pnas.1004594107 Original preclinical characterisation of ibrutinib (PCI-32765) demonstrating BTK inhibition and in vivo efficacy.
- Xiao L, Salem JE, Bhattacharya S, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation. 2020;142(25):2443–2455. doi:10.1161/CIRCULATIONAHA.120.049210 Identified CSK inhibition as the off-target mechanism responsible for ibrutinib-associated atrial fibrillation.
Pharmacokinetics / Special Populations
- de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect. 2015;3(4):e00156. doi:10.1002/prp2.156 Clinical pharmacokinetic study quantifying the impact of CYP3A4 inhibitors and inducers on ibrutinib exposure.
- Marostica E, Sukbuntherng J, Loury D, et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol. 2015;75(1):111–121. doi:10.1007/s00280-014-2617-3 Population PK model characterising ibrutinib absorption, distribution, and elimination across clinical trials.
- Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796–1805. doi:10.3324/haematol.2017.171041 Pooled analysis of AF incidence, risk factors, and management across ibrutinib registration trials.